U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Aspen Sales Group - 609365 - 12/05/2024
  1. Warning Letters

CLOSEOUT LETTER

Aspen Sales Group MARCS-CMS 609365 —

Product:
Food & Beverages
Recipient:
Recipient Name
Laurie Bogle
Recipient Title
CFO
Aspen Sales Group

350 Main St., Suite 6A
Bedminster, NJ 07921-2603
United States

Issuing Office:
Division of Northeast Imports

United States

Secondary Issuing Offices

United States

Dear Ms. Bogle,

The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter CMS# 609365 dated October 07, 2020. Based on our evaluation, it appears that you have addressed the violation contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Sincerely,
/S/
Anna Alexander
Director, Compliance Branch
Division of Northeast Imports-Compliance Branch
U.S. Food and Drug Administration

Back to Top